Pre-hospital assessment of the role of adrenaline : measuring the effectiveness of drug administration in cardiac arrest (PARAMEDIC-2) : Trial protocol by Perkins, Gavin D. et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Perkins, Gavin D., Quinn, Tom, Deakin, Charles D., Nolan, Jerry, Slowther, Anne, Cooke, 
Matthew (Professor of clinical systems design), Lamb, S. E. (Sallie E.), Petrou, Stavros, 
Achana, Felix A., Finn, Judith et al.. (2016) Pre-hospital assessment of the role of adrenaline : 
measuring the effectiveness of drug administration in cardiac arrest (PARAMEDIC-2) : Trial 
protocol. Resuscitation, 108. pp. 75-81. 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/81663            
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions.   
 
This article is made available under the Attribution-NonCommercial-NoDerivatives 4.0 (CC 
BY-NC-ND 4.0) license and may be reused according to the conditions of the license.  For 
more details see: http://creativecommons.org/licenses/by-nc-nd/4.0/       
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
CP
E
(
G
A
F
K
R
C
a
b
c
d
e
f
g
h
M
i
j
k
l
m
n
o
p
a
A
R
R
A
K
A
C
R
V
a
h
0
nResuscitation 108 (2016) 75–81
Contents lists available at ScienceDirect
Resuscitation
jou rn al hom ep age : w ww.elsev ier .com/ locate / resusc i ta t ion
linical  paper
re-hospital  Assessment  of  the  Role  of  Adrenaline:  Measuring  the
ffectiveness  of  Drug  administration  In  Cardiac  arrest
PARAMEDIC-2):  Trial  protocol
avin  D.  Perkinsa,b,∗, Tom  Quinnc, Charles  D.  Deakind,e, Jerry  P.  Nolanf,g, Ranjit  Lall a,
nne-Marie  Slowthera, Matthew  Cookea,b, Sarah  E.  Lambh,  Stavros  Petroua,
elix  Achanaa,  Judith  Finni,j,k, Ian  G.  Jacobs i,j,k,1, Andrew  Carsonl, Mike  Smytha,l,
yee  Hanm,  Sonia  Byersm,  Nigel  Reesn, Richard  Whitﬁeldn,  Fionna  Mooreo,
achael  Fothergill a,o,  Nigel  Stallardp, John  Longa,  Susie  Henningsa, Jessica  Hortona,
harlotte  Kayea, Simon  Gatesa
Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7AL, UK
Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK
Faculty of Health, Social Care and Education, Kingston University London and St. George’s, University of London, London SW17 0RE, UK
Respiratory BRU, University Hospital Southampton SO16 6YD, UK
South Central Ambulance Service NHS Foundation Trust, Otterbourne, UK
School of Clinical Sciences, University of Bristol, Bristol BS8 1TH, UK
Department of Anaesthesia and Intensive Care Medicine, Royal United Hospital, Bath BA1 3NG, UK
Kadoorie Centre for Critical Care Research and Education, John Radcliffe Hospital, Nufﬁeld Department of Orthopaedics, Rheumatology and
usculoskeletal Sciences, University of Oxford, Oxford OX3 9DU, UK
Department of Epidemiology and Preventive Medicine, School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
Prehospital, Resuscitation and Emergency Care Research Unit (PRECRU), School of Nursing, Midwifery and Paramedicine, Curtin University, Perth, Australia
St John Ambulance Western Australia, Belmont, Australia
West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill DY5 1LX, UK
North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne NE15 8NY, UK
Welsh Ambulance Services NHS Trust, Denbighshire, Wales LL17 0RS, UK
London Ambulance Service NHS Trust, 8-20 Pocock Street, London SE1 0BW, UK
Statistics and Epidemiology, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 29 January 2016
eceived in revised form 13 July 2016
ccepted 26 August 2016
a  b  s  t  r  a  c  t
Despite  its  use  since  the  1960s,  the  safety  or  effectiveness  of  adrenaline  as  a treatment  for  cardiac  arrest
has never  been  comprehensively  evaluated  in a  clinical  trial.  Although  most  studies  have  found  that
adrenaline  increases  the chance  of  return  of spontaneous  circulation  for short  periods,  many  studies
found  harmful  effects  on  the brain  and  raise concern  that adrenaline  may  reduce  overall  survival  and/or
good  neurological  outcome.  The  PARAMEDIC-2  trial  seeks  to  determine  if  adrenaline  is  safe  and  effectiveeywords: in  out-of-hospital  cardiac  arrest.
drenaline
ardiac arrest
andomised controlled trial
asopressor
This is a pragmatic,  individually  randomised,  double  blind,  controlled  trial  with  a parallel  economic
evaluation.  Participants  will  be  eligible  if they  are  in cardiac  arrest  in  the  out-of-hospital  environment
and  advanced  life support  is  initiated.  Exclusions  are  cardiac  arrest  as  a result  of  anaphylaxis  or  life
threatening  asthma,  and  patient  known  or appearing  to be  under  16  or pregnant.
8000  participants  treated  by 5 UK  ambulance  services  will  be randomised  between  December  2014
and  August  2017  to adrenaline  (intervention)  or placebo  (control)  through  opening  pre-randomised  drug
 A Spanish translated version of the summary of this article appears as Appendix in the ﬁnal online version at http://dx.doi.org/10.1016/j.resuscitation.2016.08.029.
∗ Corresponding author at: Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7AL, UK.
E-mail address: g.d.perkins@warwick.ac.uk (G.D. Perkins).
1 Professor Ian Jacobs made a substantial input into the conception and design of this study but died before the manuscript was published. We acknowledge his support
nd  contribution
ttp://dx.doi.org/10.1016/j.resuscitation.2016.08.029
300-9572/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
c-nd/4.0/).
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packs.  Clinical  outcomes  are  survival  to 30 days  (primary  outcome),  hospital  discharge,  3, 6 and  12 months,
health  related  quality  of  life,  and  neurological  and cognitive  outcomes  (secondary  outcomes).
Trial  registration  (ISRCTN73485024).
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The drug adrenaline has been an integral component of
dvanced life support from the birth of modern cardiopulmonary
esuscitation in the early 1960s. In guidelines written originally
n 1961, Peter Safar recommended the use of very large doses
f adrenaline: 10 mg  intravenously or 0.5 mg  intra-cardiac1 and
drenaline has continued to be recommended ever since. The Inter-
ational Liaison Committee on Resuscitation (ILCOR) synthesised
he available evidence for adrenaline in 20102 and re-assessed the
vidence in October 20153 noting that whilst it may  improve the
eturn of spontaneous circulation (ROSC) and short-term survival,
here is insufﬁcient evidence to know if adrenaline had beneﬁcial
r harmful effects on survival to discharge from hospital and on
eurological outcomes. ILCOR has called for placebo-controlled tri-
ls to evaluate the use of any vasopressor in adult and paediatric
ardiac arrest.
ummary of clinical evidence
At the time of initiating the study, a systematic review of the
iterature identiﬁed two relevant randomised, placebo controlled
rials and 16 observational studies.4 The PACA trial,5 aimed to enrol
000 patients but at the time the study closed, only 601 patients had
een randomised. The relatively small numbers led to the results
aving large uncertainty. ROSC [short term survival] was  higher in
hose receiving adrenaline (64/272 (23.5%) vs. 22/262 (8.4%); OR
.4, 95% CI 2.0–5.6), but there was not clear evidence of a beneﬁt in
urvival to hospital discharge [long term survival]: adrenaline 11
4.0%) vs. placebo 5 (1.9%) (OR 2.2, 95% CI 0.7–6.3). In addition to
he study’s imprecision, interpretation of the ﬁndings is limited by
 large number of post randomisation exclusions (n = 67, 11%).
A second randomised study compared intravenous (IV) cannu-
ation and injection of drugs (including adrenaline) versus no IV
annula or drugs amongst 851 patients with OHCA.6 The patients in
he IV group had better short-term survival (ROSC 165/418 (40%) vs.
07/433 (25%), OR 1.99, 95% CI 1.48–2.67)); however, there was  no
lear difference in long term survival outcomes (survival to hospi-
al discharge (IV arm 44/418 (10.5%) vs. no IV arm 40/433 (9.2%) OR
.16 (95%CI 0.74–1.82), or favourable neurological outcome (Cere-
ral Performance Category [CPC] 1–2: IV 9.8% vs. no IV 8.1% OR 1.24
0.77–1.98). The higher rate of ROSC was seen mainly in the patients
ith initial non-shockable rhythms (asystole and PEA): 29% (IV) vs.
1% (no IV). The rate of ROSC was 59% (IV) vs. 53% (no IV) in those
atients with an initial rhythm of VF/VT.
Observational studies allow large amounts of data to be col-
ected but are often limited by bias, and confounding. Statistical
echniques can be used to adjust for differences in measured
onfounding variables, however unknown confounders may  still
ead to biased results. This is illustrated by two propensity score
atched analyses from the same cohort of patients. The studies
sed slightly different statistical models produced different results.
ne showed worse long term neurologically outcomes (odds ratio
.21, 95% conﬁdence interval 0.1 to 0.44),7 whereas the other
tudy showed marginal beneﬁt (1.57, 1.04–2.37).8 Meta-analyses
f such studies should be interpreted with caution but show bet-
er short term outcomes (return of spontaneous circulation) andblished  by  Elsevier  Ireland  Ltd. This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
either no difference or worse long term survival and neurological
outcomes.9,10 (Table 1)
This creates the paradox of better short term survival at the
cost of worse long term outcomes, in other words a ‘double-edged
sword’.11
Mechanisms of action
A detailed review of the mechanism of action for adrenaline in
cardiac arrest has been published previously.12 In brief, potentially
beneﬁcial effects are attributed to stimulation of  receptors in
vascular smooth muscle, causing vasoconstriction. This increases
aortic diastolic pressure, which in turn leads to increased coro-
nary perfusion pressures, which is associated with an increased
chance of ROSC. Potentially harmful effects are  and  receptor
mediated and include reduced cerebral micro-vascular blood ﬂow
and exacerbation of cerebral injury,13–15 cardiovascular instability
after ROSC6,16 and adverse immunomodulatory17,18 and metabolic
effects.19–22 Experimental studies have shown that -blocker treat-
ment may mitigate some of these harms.23
Clinicians’ views on the safety and effectiveness of adrenaline
To assess attitudes of the UK clinical community on the role
of adrenaline for the treatment of cardiac arrest we  conducted
a written survey of 213 attendees (doctors, nurses, paramedics)
at the Resuscitation Council (UK) Annual Scientiﬁc Symposium
in September 2012. Respondents expressed their agreement to a
series of statements on a 7 point Likert scale (1 = strongly disagree,
7 strongly agree). Respondents reported that they believed that
adrenaline increased short term survival (median score 6 (IQR 6–7),
but disagreed that it improved long term outcomes (median score
2 (IQR 2–3)). There was greatest uncertainty about the balance of
risks and beneﬁts of IV adrenaline (Fig. 1a). Respondents felt the
most pressing future research need for the NHS was a trial compar-
ing adrenaline to placebo (Fig. 1b).
Summary
The use of adrenaline in cardiac arrest increases the chances that
the heart is restarted [ROSC] but there remains doubt as to whether
this is translated into improved or worse long term survival and
neurological outcomes. The Pre-hospital Assessment of the Role
of Adrenaline: Measuring the Effectiveness of Drug administration
In Cardiac arrest (PARAMEDIC-2) trial seeks to establish whether
the use of intravenous adrenaline, administered in accordance with
current cardiac arrest guidelines is helpful or harmful.
Trial design
Trial summaryThis is a pragmatic, individually randomised, double blind, con-
trolled trial and parallel economic evaluation.
The primary objective of this trial is to determine the clinical
effectiveness of adrenaline in the treatment of OHCA. The pri-
mary outcome will be 30-day survival. Secondary objectives of the
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Table  1
Summary ﬁndings from two meta-analyses of a total of 1 randomised trial and 18 observational studies.9,10
Setting Study type Pre-hospital ROSC Survival to discharge/30
days
Survival with
favourable
neurological outcome
Loomba OHCA
n = 655 853
1 randomised
13 observational
Odds ratio 2.84
(95% CI 2.28–3.54)
Odds ratio
1  month
1.03
(95% CI 0.70–1.34)
Discharge 0.82
(95% CI 0.46–1.48)
0.51
(95% CI 0.31–0.84)
Atiksawedparit OHCA
n = 637,078
1 randomised
14 observational
Relative risk
2.89
(95% CI: 2.36,−3.54)
Relative risk
0.69,
(95% CI 0.48–1.00)
Not reported
Fig. 1. Clinicians views on the safety and effectiveness of adrenaline and the need for a
outweigh the beneﬁt (b) Histogram showing responses to the question “In a trial, the stan
Table 2
Trial outcomes.
Primary clinical
outcome
Survival to 30 days post cardiac arrest.
Secondary clinical
outcomes
Survived event (sustained return of spontaneous
circulation (ROSC), with spontaneous circulation
until admission and transfer of care to medical staff
at the receiving hospital)
Survival to and neurological outcomes at hospital
discharge (the point at which the patient is
discharged from the hospital acute care unit
regardless of neurological status, outcome or
destination)
Survival to and neurological outcome at 3,6 and 12
months (IQCODE and “Two simple questions”,
Modiﬁed Rankin Scale (mRS))
Health related quality of life at 3 and 6 months (SF12
and EQ-5D)
Cognitive outcome at 3 months (Mini Mental State
Examination (MMSE))
Anxiety and depression at 3 months (Hospital
Anxiety and Depression Scale (HADS))
Post Traumatic Stress at 3 months (PTSD civilian
checklist (PCL-C))
Hospital length of stay
Intensive care length of stay
Safety Adverse events, Serious Adverse events,
Primary economic
outcome
Incremental cost per quality-adjusted life year (QALY)
gained from the perspective of the NHS and personal
social services (PSS)
t
t
l
aSecondary economic
outcome
Cost of critical care stay (level 2/3 days)
Cost of hospital stay
Utilisation of NHS and PSS resources after discharge
Broader resource utilisation after discharge.rial are to evaluate the effects of adrenaline on short and long
erm survival, cognitive and neurological outcomes and to estab-
ish the cost-effectiveness of using adrenaline. The study outcomes
re summarised in Table 2. Further information on the selection trial. (a) Histogram reporting overall, the risks of IV adrenaline in cardiac arrest
dard dose of adrenaline should be compared with which of the following?”.
and measurement of outcome measures is available in the on-line
supplement.
The study seeks to enrol 8000 participants in 3 years which
includes a 6-month internal pilot to evaluate whether recruitment
rate, compliance with allocated intervention and that the approach
to data collection and follow-up works effectively. The pilot phase
started in December 2014 and the main trial started in July 2015.
The pilot ran seamlessly into the main trial and the data from the
pilot will be included in the main study results. The study ﬁndings
should be available for presentation in 2018. The trial ﬂow diagram
is presented in Fig. 2.
The study is being co-ordinated by Warwick Clinical Trials Unit
in partnership with ﬁve research sites: London Ambulance Service
NHS Trust, North East Ambulance Service NHS Foundation Trust,
South Central Ambulance Service NHS Foundation Trust, Welsh
Ambulance Service NHS Trust, West Midlands Ambulance Service
NHS Foundation Trust.
Eligibility criteria
Patients will be eligible if they are in cardiac arrest in an out of
hospital environment and advanced life support is initiated by an
ambulance service clinician. Exclusion criteria at the time of arrest
will be: known or apparent pregnancy; known or apparently aged
under 16 years; cardiac arrest thought to be caused by anaphylaxis
or life-threatening asthma; adrenaline given prior to arrival of the
enrolling ambulance service clinician.
Randomisation and blindingRandomisation will use a system of pre-randomised, numbered
treatment packs containing 10 pre-ﬁlled syringes of adrenaline
(1 mg)  or placebo. The randomisation allocation will be 1:1 (active:
control). The packs for either intervention will be identical in
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ppearance thus ensuring allocation concealment for the attend-
ng clinicians, Research Paramedics and trial administration team.
he pre-randomised sequence will be prepared by the trial statisti-
ian and only he/she will be able to link the drug pack number to the
llocation of adrenaline or placebo. However, all statistical analyses
ill use masked allocation to avoid the revelation of the true alloca-
ion. The sequence will be generated using simple randomisation to
nsure approximate balance between numbers of patients receiv-
ng adrenaline and placebo within each ambulance service. When
mbulance service personnel identify an eligible patient, randomi-
ation will be achieved by opening one of the packs carried by the
ehicle attending the arrest.
rial intervention
Participants will receive resuscitation according to the Resusci-
ation Council (UK) Advanced Life Support Guidelines, except that
tandard adrenaline will be substituted with the trial drug drawn
rom a single trial treatment pack.
Participants enrolled in the intervention arm will receive
drenaline 1 mg  contained in 3 ml  pre-ﬁlled syringes. Participants
n the control arm will receive 0.9% saline formulated as identical ﬂow diagram.
3 ml  pre-ﬁlled syringes. Each treatment pack will contain 10 treat-
ment doses. After this clinicians will review the appropriateness
of continued resuscitation and either transfer to hospital or termi-
nate resuscitation efforts. Trial interventions will cease when the
patient arrives in an emergency department or when resuscitation
efforts are discontinued. Treatment after admission to hospital will
be at the discretion of the attending clinician.
Sample size
The basis for our sample size estimate is summarised in the elec-
tronic supplement. The target sample size will be 8000, which is
expected to give a width of the 95% CI for the risk ratio of approx-
imately 0.4 or slightly less; for a risk ratio of 1.25 the 95% CI is
1.07–1.46, and for risk ratio of 1.0 it is 0.84–1.19. There is a trade-
off between precision and practicality in setting a target sample
size; above 8000, there is only a small improvement in precision,
but the difﬁculty and time needed to recruit this number increase
signiﬁcantly. Using a conventional signiﬁcance test based sample
size calculation, this sample size would give 93% power to detect
an increase in survival of 2% (from 6% to 8%), with (two-sided) type
I error rate of 5%. We  expect very few missing data for survival
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utcomes; in a previous trial we ascertained survival status for over
9% of randomised patients, and we have therefore not adjusted the
ample size estimates to account for missing data.24
thical/legal considerations and trial registration
We  have previously reported our assessment of the ethical con-
iderations for this trial.25 Further details are contained in the
n-line supplementary material.
The Oxford Research Ethics Committee C (REC: 14/SC/0157) and
edical Healthcare Regulatory Authority (MHRA) (EudraCT:2014-
00792-11) approved the study protocol. The trial registration
umber is ISRCTN73485024.
rovision of general information about the trial
We  issued a national press release in August 2014 which
eceived substantial national and regional media coverage. Addi-
ional information has been distributed by ambulance services in
ach of the regions. In addition study information leaﬂets (Fig. 3)
ave been distributed via pharmacies, emergency departments,
ocal councils, libraries, Register of Births and Deaths ofﬁces, Foun-
ation Trust members and general practitioner surgeries. Patient
nd public facing information was designed with extensive input
rom our lay advisory group. Full details about the trial are available
n the study website: www.warwick.ac.uk/paramedic2.
or those that do not wish to participate
We  have developed a system to allow individuals to decline
articipation in the trial based on the approach used by the North
merican Resuscitation Outcome Consortium. An online form can
e completed on the website or the team can be contacted by phone
r email. A stainless steel “No Study” bracelet will be issued to
he person’s home address and with the person’s permission, their
ome address will be passed to their local ambulance service to
egister their wishes. They will also be asked to inform those close
o them of their wishes and that those wishes will be respected
y the treating paramedics. Paramedics are trained to look for the
racelet.
nrolment, consent and follow-up
Cardiac arrest outside a hospital is a sudden, unexpected event.
he victim becomes unconscious rapidly and thus loses men-
al capacity. Treatment must be initiated immediately making it
mpractical to obtain informed consent from the patient or legal
epresentatives. Authorisation to enrol patients under waiver of
onsent regulations was granted by the Research Ethics Commit-
ee. Once the initial emergency has passed, patients (or their legal
epresentative (usually a relative) if the patient lacks capacity) will
e provided with written information about the study and consent
o continue in the follow-up elements of the study will be sought.
ull information about our approach to informing patients and their
elatives about the trial and their follow-up can be found in the
n-line supplement.
tatistical analysis
The primary analysis will be by intention to treat, comparing the
utcomes between all participants randomised to adrenaline and
ll those randomised to placebo.
Results will be presented as estimates of the treatment effect
ith 95% conﬁdence intervals. Dichotomous outcomes (survival to
0 days, survived event, and survival to hospital discharge, 3, 6
nd 12 months) will be analysed using logistic regression models,ion 108 (2016) 75–81 79
both unadjusted and adjusted for appropriate covariates which are
selected a priori in agreement with the Data Monitoring Committee
and Trial Steering Committee. Survival and other time to event out-
comes will be analysed using time to event techniques. Continuous
outcomes will be analysed by regression methods and the results
presented as the difference in means between the groups and 95%
conﬁdence intervals. Modiﬁed Rankin Scale (mRS) will be analysed
by ordinal logistic regression and presented using odds ratios and
95% conﬁdence intervals. Reporting of analyses will follow CON-
SORT guidelines.
The following exploratory analyses will be used to investigate
potential moderators of the treatment effect of adrenaline by ﬁt-
ting interaction terms in the logistic or linear regression models
described above:
• Age
• Witnessed cardiac arrest versus not witnessed
• Bystander CPR versus no bystander CPR
• Type of initial rhythm (VF/VT, PEA, Asystole)
• Time of 999 call to administration of adrenaline
• Aetiology of cardiac arrest (presumed cardiac versus non-
cardiac).
Economic evaluation
The economic evaluation will be conducted from the recom-
mended NHS and personal social services (PSS) perspective.26
Sources for data collection are summarised in the on-line sup-
plement. The main results of the economic evaluation will be
expressed in terms of incremental cost per quality-adjusted life
year (QALY) gained. This incremental cost-effectiveness analysis
will be expressed as: (i) incremental cost per additional survivor
to 30 days post-cardiac arrest; (ii) incremental cost per addi-
tional neurologically intact (modiﬁed Rankin Scale (mRS) 0–3)
survivor; and (iii) incremental cost per quality-adjusted life year
(QALY) gained. Results will be presented using incremental cost-
effectiveness ratios (ICERs) and cost-effectiveness acceptability
curves (CEACs) generated via non-parametric bootstrapping. Het-
erogeneity in the trial population will be explored by formulating
a net-beneﬁt value for each patient from the observed costs and
effects, and then constructing a regression model with a treatment
variable and covariates such as age, gender, duration of OHCA and
study site. The magnitude and signiﬁcance of the coefﬁcients on
the interaction between the covariates and the treatment variable
should provide an estimate of the cost-effectiveness of adrenaline
by sub-group. Due to the known limitations of within-trial eco-
nomic evaluations27 we will also construct a decision-analytical
model to model beyond the parameters of the proposed trial the
cost-effectiveness of adrenaline in this clinical population. Survival
analysis models will be used to estimate life expectancy with and
without adrenaline beyond the time horizon of the trial. Long term
costs and health consequences will be discounted to present values
using discount rates recommended for health technology appraisal
in the United Kingdom. A series of probabilistic sensitivity analy-
ses will be undertaken to explore the implications of parameter
uncertainty on the incremental cost-effectiveness ratios.
Oversight
The study is sponsored by the University of Warwick. A Trial
Steering Committee (TSC) (with a majority of independent mem-
bers, including patient/public representatives) will meet at least
annually to maintain oversight of the trial. A Data Monitoring
Committee (DMC) of independent experts with relevant clinical
research, and statistical experience will monitor the accumulat-
ing interim data every 3 months or as they consider appropriate. At
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ach interim point, the monitoring of the study involves compar-
son of the primary outcome against statistical boundaries which
ave been constructed using the alpha spending approach. In par-
icular, the overall desired signiﬁcance level has been maintained
sing the Pocock and O’Brien Fleming type spending function. The
pper and lower boundaries have adopted asymmetric stoppingation leaﬂets.
rules, which has allowed us to be conservative for harm but less
conservative for efﬁcacy at early stages of trial. The DMC  will advise
the Chair of the TSC if, in their view, the randomised comparisons
have provided both (i) ‘proof beyond reasonable doubt’ that for
all, or some, the treatment is clearly indicated or clearly contra-
indicated and (ii) evidence that might reasonably be expected
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26. National Institute for Clinical Excellence. Guide to the methods of health tech-G.D. Perkins et al. / Res
o materially inﬂuence future patient management. Following a
eport from the DMC, the Steering Committee will decide what
ctions, if any, are required. Unless the DMC  request cessation of
he trial the Steering Committee and the collaborators will remain
gnorant of the interim results.
atient and public involvement (PPI)
We  sought guidance from patients and the public during the
onception, design and running of the trial. We  held a community
ngagement event (supported by West Midlands South CLRN) in
ate November 2012 where we presented the scientiﬁc rationale
ehind this trial to a group of 280 lay-people who  were inter-
sted in ﬁrst aid. After preparing the talk in collaboration with
ne of our PPI representatives (John Long) to ensure concepts were
resented in plain, understandable English, we  delivered the pre-
entation and addressed questions/queries from the group. We
xplained the concept of short term and longer-term outcomes
nd brieﬂy sought community views about priorities for outcomes
nd their views on a trial of adrenaline for out of hospital cardiac
rrest. We  received responses from 243 participants. Ninety-ﬁve
ercent of respondents prioritised long-term survival over short-
erm survival (hours to days). Participants broadly agreed there
as a need for further research about adrenaline as a treatment
or cardiac arrest (86% agreed, 8% neither agree nor disagreed, 6%
isagreed). Patient and public representatives serve on our trial
anagement group and study steering committee. In addition we
onsulted user groups via the Clinical Research Ambassador Group
nd University/User Teaching and Research Action Partnership and
esuscitation Council (UK) and established a patient advisory group
o assist with the design of supporting material and our approach
o sharing information about the study.
onclusion
The International Liaison Committee on Resuscitation has high-
ighted uncertainty about the safety and effectiveness of adrenaline
s a treatment for cardiac arrest. The PARAMEDIC-2 trial is a prag-
atic, individually randomised, double blind, controlled trial and
conomic evaluation designed to determine if adrenaline affects 30
ay survival in victims of out-of-hospital cardiac arrest.
unding
This project is funded by the National Institute for Health
esearch HTA Programme (project number HTA – 12/127/126)
This paper presents independent research funded by the
ational Institute for Health Research (NIHR). The views expressed
re those of the author(s) and not necessarily those of the NHS, the
IHR or the Department of Health.
GDP is supported as a Director of Research for the Intensive Care
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